Navigation Links
Researchers discover genetic changes that make some forms of brain cancer more aggressive
Date:10/1/2010

NEW YORK, October 1, 2010--A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,--an MSKCC surgeon, researcher and the Director of the Brain Tumor Center--and was published in the October 1 issue of the journal Genes & Development.

Glioblastoma has several subtypes, which are characterized by different genetic changes found in the tumor cells. One common subtype is characterized by cells with increased signaling from a protein called platelet-derived growth factor receptor (PDGFR). In this study, which involved screening patients' tumor samples for PDGFR mutations, the researchers were surprised to find that almost half of all glioblastomas with excess copies of the PDGFR gene also had rearrangements in the gene itself, creating proteins that are continually turned on. These rearrangements were either shortened forms of the protein or involved the fusion of the protein to another receptor. Fusion genes have not been found in brain tumors previously but are well studied in certain types of leukemia, and more recently have been found in some solid tumors as well.

Much of the team's work was made possible by data coming from The Cancer Genome Atlas (TCGA), an effort funded by the National Institutes of Health to understand the molecular basis of cancer. Glioblastoma is one of three forms of cancer that has been studied in detail as part of TCGA's initial pilot phase, along with ovarian cancer and lung cancer.

The presence of the rearrangements in the PDGFR gene suggest that these specific tumors have evolved to be dependent on signaling through this receptor, a target for several drugs under development. According to the researchers, the recent study suggests that more effort needs to be put into identifying exactly which subtype of glioblastoma a patient has in order for therapies to be targeted appropriately.


'/>"/>

Contact: Jeanne D'Agostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Researchers find no difference in drugs for macular degeneration
2. Researchers advance biosynthesis of potent anti-cancer drug Taxol
3. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
4. Researchers at the University of Granada associate trigger points with shoulder injury
5. Researchers to study effects of Mass. health reform
6. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
7. Researchers use CT to predict heart disease
8. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
9. Sugary sports drinks mistakenly associated with being healthy, say UTHealth researchers
10. Researchers create first molecule blocks key component of cancer genes on-off switch
11. Researchers create first molecule-blocks key component of cancer genes on-off switch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Los Angeles, California (PRWEB) , ... July 19, 2017 , ... ... which found that most successful weight loss surgery patients who had received a body ... Angeles Area health and beauty clinic Beverly Hills Physicians (BHP), which provides both types ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed memoir ... public high school music and drama teacher who was a summa cum laude graduate ... a “Teacher of the Year” award. After her retirement from public school, Lynn continued ...
(Date:7/18/2017)... , ... July 18, 2017 , ... CannaKids, a California ... cannabis oils, announced today that at the WORLDZ Summit, taking place in Hollywood ... on the therapeutic benefits of medical cannabis for both pediatric and adult patients, and ...
(Date:7/18/2017)... VA (PRWEB) , ... July 18, 2017 , ... ... 11) , What Strategic Decisions Do You Need to Consider?, **An FDAnews ...      , 42 CFR Part 11, “Final Rule for Clinical Trials Registration ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... basis, partners with the best medical professionals who offer the most effective and ... medical professional in their network, ensuring that each patient receives prompt and courteous ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/5/2017)... July 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured ... physics and manufacturing combine to progress molecular radiotherapy imaging. ... systems are unable to accurately quantify the radiation absorbed by ... regarding the success of this radiotherapy treatment has been available ... ...
Breaking Medicine Technology: